These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 36854167)

  • 1. Efficacy of Erbium YAG laser treatment in overactive bladder syndrome: a randomized controlled trial.
    Chiengthong K; Bunyavejchevin S
    Menopause; 2023 Apr; 30(4):414-420. PubMed ID: 36854167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of non-ablative vaginal erbium:YAG laser treatment as a novel surgical treatment for overactive bladder syndrome: comparison with anticholinergics and β3-adrenoceptor agonists.
    Okui N
    World J Urol; 2019 Nov; 37(11):2459-2466. PubMed ID: 30687908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Combination Therapy With Vaginal and Urethral Erbium-Doped Yttrium-Aluminum-Garnet (Er:YAG) Laser for Overactive Bladder With Urinary Incontinence.
    Okui N; Okui MA
    Cureus; 2024 Jun; 16(6):e62363. PubMed ID: 39006699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Number of vaginal lactobacilli in postmenopausal women with vaginal atrophy before and after treatment with erbium-YAG laser: a randomized sham-controlled trial.
    Panyawongudom N; Panyakhamlerd K; Suwan A
    BMC Womens Health; 2023 Sep; 23(1):513. PubMed ID: 37752478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined Tolterodine and Vaginal Estradiol Cream for Overactive Bladder Symptoms After Randomized Single-Therapy Treatment.
    Ellington DR; Szychowski JM; Malek JM; Gerten KA; Burgio KL; Richter HE
    Female Pelvic Med Reconstr Surg; 2016; 22(4):254-60. PubMed ID: 26945271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective randomized trial comparing the use of tolterodine or weighted vaginal cones in women with overactive bladder syndrome.
    Yüce T; Dökmeci F; Çetinkaya ŞE
    Eur J Obstet Gynecol Reprod Biol; 2016 Feb; 197():91-7. PubMed ID: 26720597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
    Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
    Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.
    Ginsberg D; Schneider T; Kelleher C; Van Kerrebroeck P; Swift S; Creanga D; Martire DL
    BJU Int; 2013 Aug; 112(3):373-85. PubMed ID: 23826844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is vaginal fractional CO2 laser treatment effective in improving overactive bladder symptoms in post-menopausal patients? Preliminary results.
    Perino A; Cucinella G; Gugliotta G; Saitta S; Polito S; Adile B; Marci R; Calagna G
    Eur Rev Med Pharmacol Sci; 2016 Jun; 20(12):2491-7. PubMed ID: 27383297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and safety of acupuncture for elderly overactive bladder population in Hong Kong: study protocol for a randomized controlled trial.
    Chan YT; Zhang HW; Guo YQ; Chan TNH; Kwan YK; Lee CK; Ngan K; Lin ZX
    Trials; 2018 Jul; 19(1):376. PubMed ID: 30005707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of non-ablative laser treatment on overactive bladder symptoms, urinary incontinence and sexual function in women with urodynamic stress incontinence.
    Lin YH; Hsieh WC; Huang L; Liang CC
    Taiwan J Obstet Gynecol; 2017 Dec; 56(6):815-820. PubMed ID: 29241926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
    Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
    BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome.
    Tseng LH; Wang AC; Chang YL; Soong YK; Lloyd LK; Ko YJ
    Neurourol Urodyn; 2009; 28(1):47-51. PubMed ID: 19089890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms.
    Serels SR; Toglia MR; Forero-Schwanhaeuser S; He W
    Curr Med Res Opin; 2010 Oct; 26(10):2277-85. PubMed ID: 20707767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The concomitant use of fesoterodine and topical vaginal estrogen in the management of overactive bladder and sexual dysfunction in postmenopausal women.
    Chughtai B; Forde JC; Buck J; Asfaw T; Lee R; Te AE; Kaplan SA
    Post Reprod Health; 2016 Mar; 22(1):34-40. PubMed ID: 26883688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.
    Chapple C; Herschorn S; Abrams P; Sun F; Brodsky M; Guan Z
    Eur Urol; 2009 Sep; 56(3):534-41. PubMed ID: 19070418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diary and patient-reported outcomes in patients with severe overactive bladder switching from tolterodine extended release 4 mg/day to solifenacin treatment: An open-label, flexible-dosing, multicentre study.
    Swift SE; Siami P; Forero-Schwanhaeuser S
    Clin Drug Investig; 2009; 29(5):305-16. PubMed ID: 19366272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale and design for fractional microablative CO
    Flint R; Cardozo L; Grigoriadis T; Rantell A; Pitsouni E; Athanasiou S
    Climacteric; 2019 Jun; 22(3):307-311. PubMed ID: 30676818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
    Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
    BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of vaginal lasers in the treatment of urinary incontinence and overactive bladder, systematic review.
    Alsulihem A; Corcos J
    Int Urogynecol J; 2021 Mar; 32(3):553-572. PubMed ID: 33175226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.